New trends in patient management: Risk-based therapy for febrile patients with neutropenia

Clinical Infectious Diseases

Volumn 29, Issue 3, 1999, Pages 515-521

  Rolston, Kenneth V I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZLOCILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; METICILLIN; MEZLOCILLIN; NAFCILLIN; OFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PARENTERAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0032880733     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598624     Document Type: Review

References (26)

1. Bodey GP. Overview of the problem of infection in the immunocompromised host. Am J Med 1985;79(suppl):56-61.
2. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationship between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1996;64:328-39.
3. Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993;328:1323-32.
4. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Arch Intern Med 1988;148: 2501-68.
5. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia. A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
6. Hughes WT, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America: guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161: 381-96.
7. Hughes WT, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25:551-73.
8. De Jongh CA, Joshi JH, Newman KA, et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986;80:96-100.
9. Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med 1984;144:1845-51.
10. Rubin M, Hathorn JW, Pizzo PA. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 1988;6:167-84.
11. Bodey GP, Grose WE, Keating MJ. Use of trimethoprim/sulfamethoxazole for treatment of infections in patients with cancer. Rev Infect Dis 1982;4:579-85.
12. Haron E, Rolston KIV, Cunningham C, et al. Oral ciprofloxacin therapy for infection in cancer patients. J Antimicrob Chemother 1989;24: 955-62.
13. Malik IA, Abbas Z, Karim M. Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092-6.
14. Talcott JA, Whalen A, Clark J, et al. Home antibiotic therapy for low risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12: 107-14.
15. Kelsey SM, Collins PW, Decord C, et al. A randomized study of teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients. Br J Haematol 1990;76(suppl 2):10-3.
16. Chan CC, Oppenheim BA, Anderson H, et al. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother 1989;33:87-91.
17. Flaherty JP, Watley D, Eldin B, et al. Multicenter randomized trial of ciprofloxacin plus amikacin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med 1989;87(suppl 5A):2785-825.
18. 17a. Rolston KVI, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenic patients at low risk. Infect Dis Clin North Am 1996;10:223-37.
19. Lav RC, King SM, Richardson SE. Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatr Hematol Oncol 1994;11:417-21.
20. Bash RO, Katz JA, Cash JV, et al. Safety and cost-effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74:189-96.
21. Malik IA, Khan WA, Aziz A, et al. Self-administered antibiotic therapy for chemotherapy-induced low-risk febrile neutropenia in patients with non-hematologic neoplasms. Clin Infect Dis 1994;19:522-7.
22. Malik IA, Kahan WA, Karim M, et al. Feasibility of out-patient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-31.
23. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-6.
24. Rolston KVI, Ruhenstein EB, Elting LS, et al. Ambulatory management of febrile episodes in low risk neutropenic patients [abstract no. 2235]. In: Program and abstracts of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
25. Gardembas-Pain M, Desablens B, Sensebe L, et al. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 1991;2:485-7.
26. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. Cancer 1999;85:213-9.